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Abstract
Objective: Though the relationship between glucose-6-phosphate dehydrogenase (G6PD) deficiency and type 2
diabetes (T2D) has been reported, their interaction to influence oxidative stress is not fully understood. This study
was conducted to investigate the relationship between T2D and G6PD deficiency and assessed their effect on
oxidative stress.
Methodology: A total of 73 T2D and 75 non-diabetic (ND) out-patients at Enugu State University Teaching
Hospital (ESUTH) in Enugu, Nigeria were recruited. They were screened for G6PD deficiency, oxidative stress
markers; lipid peroxidation, protein peroxidation and glycated haemoglobin (HbA1c) and antioxidant enzymes;
superoxide dismutase (SOD) and catalase activities were assayed.
Results: Oxidative stress was influenced by T2D as malondialdehyde (MDA), protein carbonyl and HbA1c levels
were significantly higher (p<0.05) in T2D patients compared to ND patients. Significantly (p<0.05) decreased SOD
and catalase activity were also observed in T2D patients. G6PD deficiency and T2D showed a significant
relationship (p<0.05) in male patients (χ2=5.070; p=0.024). Moreover, there was no significant (p>0.05) interaction
between G6PD deficiency and T2D to influence oxidative stress in patients.
Conclusion: The interaction between G6PD deficiency and T2D did not influence oxidative stress though there
was a possible relationship between G6PD deficiency and T2D in male patients.
Keywords: G6PD deficiency; Type 2 diabetes; Oxidative stress;
Antioxidants; Glycated haemoglobin
Introduction
The global prevalence of diabetes is constantly increasingly. The
burden of the disease has risen from 108 million (4.7%) in 1980 to 422
million (8.5%) in 2012. More than 90% of all cases of the disease are of
type 2 diabetes (T2D) [1]. Though this disease was previously known
to be highly prevalent in developed countries, recent data indicate
rising prevalence rates in middle and low-income countries. For
instance, the current rate for Nigeria is 1.9%, translating to over 3.85
million people living with the disease. Nigeria currently has the highest
prevalence rate in Africa [2].
T2D is a disease characterised by elevated blood glucose levels as a
result of the inability of insulin to recognise its receptor and promote
the metabolism of glucose [3]. In a state of hyperglycaemia, glucose is
known to generate free radicals through several mechanisms [4].
Glucose can be autooxidised in the presence of transition metals to an
enediol radical anion which is further converted into reactive
ketoaldehydes and to superoxide anion radicals [5]. Glucose also
promotes lipid peroxidation of low density lipoprotein (LDL) via a
superoxide-dependent pathway to generate free radicals [6,7]. Glucose
can promote free radical formation by interacting with proteins to
form amadori product [8] and then advanced glycation end-products
(AGEs), including glycated haemoglobin [9,10]. These processes make
glucose a major source of free radicals in diabetes. Excessively high
levels of these free radicals lead to a state of oxidative stress [11]
causing damage to nucleic acids [12], cellular proteins [13], lipid
membranes [14] and eventually cell death. Cell damage of this nature
forms the basis for some of the secondary complications of diabetes
mellitus [15].
In response to oxidative stress, the antioxidant defence system,
constituting both the enzymatic and non-enzymatic antioxidants, is
activated to scavenge free radicals [16]. Superoxide dismutase (SOD)
emerges to dismutate superoxide anion radicals to hydrogen peroxide
(H2O2) [17]. H2O2, if not removed can be converted in the presence of
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catalase and glutathione peroxidase further degrades H2O2 [19]. For
glutathione peroxidase to reduce H2O2 to H2O and O2, it requires
reduced glutathione (GSH) [20]. In the process, GSH is converted to
oxidized glutathione (GSSG) [20] and then regenerated by glutathione
reductase which utilizes nicotinamide adenine dinucleotide phosphate
(NADPH) as the reducing agent [21] NADPH is generated by
glucose-6-phosphate dehydrogenase (G6PD), a key enzyme in the
pentose phosphate pathway [22].
G6PD is coded by an X-linked housekeeping gene in humans,
located at the telomeric region of the X-chromosome long arm (band
Xq28) [22]. G6PD deficiency is a common enzyme defect that occurs
as a result of mutation in the G6PD gene. It affects over 400 million
people worldwide with highest frequencies (5-30%) recorded in Africa,
Asia, the Mediterranean area, and the Middle East with male
presenting high prevalence than female [23-25]. The X-linkage of this
gene has important implications as hemizygous males for this gene
could either be normal or G6PD deficient while females who have two
copies of the gene G6PD gene, could either be normal, deficient
(homozygous), or intermediate (heterozygous) [23-25]. G6PD
deficient individuals are vulnerable to oxidative stress [25]. As such,
there has been considerable thought that G6PD deficiency may be
associated with oxidative stress in T2D due to insufficient or limited
production of NADPH which regenerates GSH, a physiologic
antioxidant to scavenge glucose-generated free radicals [26]. Reports of
studies investigating the relationship between G6PD deficiency and
diabetes have been inconsistent with contrasting findings [27-29].
Moreover, majority of these studies only investigated the relationship
between G6PD deficiency and diabetes as well as their independent
influence on oxidative stress [27-29] without assessing the interaction
between G6PD deficiency and T2D on oxidative stress. Hence, this
study addressed this gap by assessing the relationship between G6PD
deficiency and T2D and assessed the effect of this interaction on
oxidative stress.
Materials and Methods
Participants’ recruitment and study design
This study was conducted at Enugu State University Teaching
Hospital (ESUTH) in Enugu Nigeria. The study design was reviewed
and approved by the Ethical Committee of ESUTH Enugu, Nigeria
with approval number: ESUTHP/C-MAC/RA/034/174. Written
informed consent was obtained from all participants before the
commencement of the study. Outpatients above 30 years of age without
any critical health condition or complications of diabetes and are not
on hospital admission were recruited for the study. Breastfeeding
and/or pregnant women, HIV positive patients as well as patients
without oxidative stress related illnesses such as malaria,
atherosclerosis, hypertension, and cardiovascular diseases were
excluded from the study. Outpatients visiting the hospital were
screened for T2D by measuring their fasting blood glucose and were
considered diabetic according to IDF criteria [30] with at least one-
year history of the disease. Following the screening, a total of 148
patients were recruited which includes 73 T2D patients and 75 non-
diabetic (ND) patients. To assess the effect of T2D on oxidative stress,
lipid peroxidation, protein oxidation and glycated haemoglobin
(HbA1c) as oxidative stress markers as well as SOD and catalase were
assayed. To assess the relationship between G6PD deficiency and T2D,
and their effect on oxidative stress, the patients were further screened
for G6PD deficiency to differentiate G6PD deficient from non-
deficient patients. Also, the relationship between G6PD deficiency and
T2D was assessed independently for males and females. The study
design is summarized in Figure 1.
Figure 1: Flow diagram showing study design tree.
Data collection
Following recruitment, participants were administered a research
questionnaire which sought relevant demographic information
including age, sex, ethnicity, location and disease history. Systolic
blood pressure (SBP) and diastolic blood pressure (DBP) were
measured using an automatic sphygmomanometer. In addition,
anthropometric data including body weight, height and waist
circumference (WC) of participants were collected. Weight and height
of participants were used for the estimation of Body Mass index (BMI)
as weight (Kg)/ height2 (m2).
Laboratory analysis
Following an overnight fast, blood sample (2 ml) was collected from
participants into EDTA tubes. Whole blood was used for the
assessment of all biochemical parameters in this study. Fasting blood
glucose (FBG) was measured by finger-prick method using an
Accucheck glucometer (Roche Holding AG, Basel, Swizerland) while
the HbA1c level was assayed using the A1CNow kit (PTS diagnostics,
Indianapolis, USA).
Measurement of catalase activity
Catalase activity was measured as described by Mahmoud [31] with
slight modifications. Briefly, homogenized blood sample (100 µl) was
mixed with phosphate buffer (1 ml) and hydrogen peroxide (1 ml) as
substrate for catalase. For quality control, incubations were also
performed using water (100 µl) instead of blood sample and/or
without hydrogen peroxide.
All the tubes were well mixed and incubated at 37°C for 3 min after
which 2 ml of 5% potassium dichromate in glacial acetic acid solution
was added. The tubes were then heated at 100°C for 10 min, cooled
with tap water and centrifuged at 2500 rpm for 5 minutes to remove
precipitated protein. The absorbance of samples was recorded at 570
nm against the blank incubation carried out with water instead of
blood sample. The catalase activity (kU/L) was calculated according to
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the formula: 2.303t × ��� �0� −� × ����  with t=incubation time; S
°=Absorbance of control incubation containing catalase standard,
S=Absorbance of unknown sample, M=Absorbance of incubation
containing blood sample without hydrogen peroxide (correction
factor), Vt=Total volume of reagents in test tube, Vs=Volume of blood
sample.
Superoxide dismutase activity
Superoxide dismutase activity was determined as described by
Marklund and Marklund [32] with slight modifications. Briefly,
homogenized blood sample (50 µl) was added to 450 µl of 8 mM
pyrogallol and 500 µl of 20 mM phosphate buffer (pH 6.6). The
absorbance was read at 420 nm for 3 minutes against a blank
preparation containing distilled water instead of sample in pyrogallol
and phosphate buffer. SOD activity was expressed as U/mg. One unit
of SOD activity was defined as that amount of SOD required to cause
50% inhibition of pyrogallol autoxidation per 3 ml of assay mixture.
Measurement of lipid peroxidation
Lipid peroxidation was assessed in blood samples by a modified
method of Niehaus and Samuelsson [33] which measures the
concentration of thiobarbituric acid reactive substances (TBARS) using
a colourimetric assay. Whole blood (100 µl ) was mixed with 2 ml of a
solution containing 0.37% thiobarbituric acid, 15% trichloroacetic acid
and 0.25 mol/l hydrogen chloride reagent (1:1:1 volume ratio). The
resultant mixture was incubated at 100°C in a water bath for 30
minutes after which it was then cooled. The clear supernatant was
collected and the absorbance was taken at 535 nm against the blank to
determine the quantity of malondialdehyde (MDA) formed.
Concentration of MDA was calculated using the equation: C = AE×L
where, A=the absorbance of the sample, E=the extinction coefficient
(1.56 × 105 M-1cm-1) and L=length of the light path (1 cm).
Assessment of protein oxidation
Protein carbonyl content of blood samples was quantified, as a
marker of oxidative stress, following the method of Mesquita et al.
[34]. Blood samples (400 µl) was added to equal volume of 10 mM
DNPH (prepared in 0.5 M H3PO4) solution and incubated for 10
minutes at room temperature. This was followed by the addition of
NaOH (6M, 200 µl) and further incubated at room temperature for 10
minutes. The absorbance was measured at 450 nm against the blank
which contained equal volume of distilled water instead of blood
samples. The concentration of carbonyl content was calculated using
the equation: C = AE×L where, A=absorbance of the sample, E=molar
extinction coefficient for DNPH (22,000 M-1cm-1) and L=length of
the light path (1 cm).
Assessment of G6PD deficiency
This was assayed by the methaemoglobin reduction test described
by Brewer et al. [35].. Briefly, a mixture of whole blood (500 µl) and
glucose (0.28M, 50 µl) was transferred into a set of three tubes labeled
“Test”, “Deficient-Control” and “Normal-Control”. In the tube labeled
“Test” was added 50 µl of 0.18M sodium nitrite and 50µl of 0.4mM
methylene blue solutions. Sodium nitrite (50 µl) and equal volume of
saline solutions were added to the tube labeled “Deficient-Control”
while 100 µl of saline solution only was added to the tube labeled
“Normal-Control”. All tubes were well mixed, corked with cotton wool
and incubated at 37°C for 3 hours. After incubation, 100 µL of the
incubated mixture was transferred into new set of tubes labeled as
before followed by the addition of 5 ml of 0.02M (pH 6.6) phosphate
buffer for colour development. A dark-brown or grey colour like the
“Deficient control” was indicative of G6PD Deficient while a red
colour like the “Normal-Control” was considered as G6PD Non-
Deficient (Normal). G6PD deficient hemizygous males and
homozygous females presented a dark-brown colouration just like the
“Deficient control” while G6PD deficient heterozygous females present
an intermediate expression; a colouration between dark-brown and
grey.
Statistical Analysis
Data was analyzed using Statistical Package for Social Science
(SPSS) version 16. Quantitative values were expressed as Mean ±
Standard Error of the Mean (SEM) or Standard Deviation (SD) while
frequencies were presented as proportions and percentages. Pearson
chi-square (χ2) test was used to compare the proportional differences
of G6PD deficiency in T2D and ND patients as well as in male and
female. Mean differences of demographic, clinical data, oxidative stress
and antioxidant indices between T2D and ND patients were compared
using parametric independent sample t-test. Interaction between T2D
and G6PD deficiency for oxidative stress and antioxidant indices was
assessed by Two Way ANOVA. Pearson correlation test was used to
assess the association between continuous variables. A confidence
interval of 95% was taken and a p-value less than 0.05 was considered
statistically significant.
Results
Demographic and clinical characteristics of patients
Among the 148 study participants, 73 (49.3%) were T2D patients
while 75 (50.7%) were non-diabetic (ND) patients. Among the T2D
patients, 23 (15.3%) were male and 50 (34.0%) were female while
among the ND patients, 31 (20.8%) were male and 44 (29.9%) were
female. There was no significant sex difference between T2D and ND
patients (χ2=1.541, p=0.214). All the patients were between 30 and 92
years. Age, BMI, WC, and FBG were significantly higher (p<0.05) in
T2D patients compared to ND patients. The demographic and clinical
characteristics of the patients are summarised in Table 1.
 T2D patients (n=73) ND patients (n=75) p-value
 Male (n=23) Female (n=50) Male (n=31) Female (n=44)
Age (years) 60.17 ± 9.90 55.90 ± 9.77 52.85 ± 19.46 48.83 ± 14.914 0.011
Height (m) 1.66 ± 0.08 1.56 ± 0.064 1.69 ± 0.11 1.57 ± 0.09 0.22
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Weight (kg) 83.89 ± 19.34 76.21 ± 27.14 76.15 ± 19.78 70.61 ± 15.63 0.154
BMI (Kg/m2) 30.59 ± 6.41 31.36 ± 11.46 26.91 ± 7.29 28.55 ± 6.06 0.086
WC (cm) 100.61 ± 10.88 101.21 ± 12.69 94.95 ± 20.57 91.87 ± 12.65 0.013
SBP (mmHg) 132.72 ± 18.39 133.21 ± 22.03 136.10 ± 20.46 132.83 ± 25.66 0.745
DSP (mmHg) 80.44 ± 11.53 78.67 ± 11.38 83.80 ± 13.69 82.09 ± 18.64 0.239
FBG (mg/dL) 173.67 ± 109.50 175.79 ± 94.03 67.60 ± 39.77 67.65 ± 38.46 <0.0001
Table 1: Demographic and clinical characteristics of participants. Results are presented as Mean ± SD; SD: Standard deviation; SBP=Systolic
blood pressure; DSP=Diastolic blood pressure; FBG=Fasting blood glucose; BMI=Body mass index; WC=Waist circumference.
Effect of T2D on antioxidant and oxidative stress markers
Data on activities of antioxidant enzymes and markers of oxidative
stress in T2D and ND participants are presented in Figure 2. Catalase
activity was significantly reduced by 19% (p<0.01) in T2D patients
compared with their ND counterparts (Figure 2A). Similarly, SOD
activity was significantly reduced by 20% (p<0.05) in T2D participants
(Figure 2A). However, 1.4-fold significant increase (p<0.001) in blood
MDA concentration was observed in T2D participants compared to
their ND counterparts (Figure 2B). A similar upward trend was
observed for protein carbonyl in T2D participants (1.4-fold, p<0.001,
Figure 2B). Expectedly, average HbA1c values in the T2D population
was 1.9-fold significantly higher (p<0.01) compared to ND participants
(Figure 2C).
Figure 2: Oxidative stress indices among T2D and ND patients.
Values are expressed as mean ± SEM with n=75 for control patients
(ND) and n=73 for T2D patients (T2D). ***p<0.001, **p<0.01,
*p<0.05 compared with control patients for each parameter.
Effects of G6PD deficiency on antioxidant and oxidative
stress markers
The influence of G6PD deficiency on activities of antioxidant
enzymes and markers of oxidative stress in T2D and ND participants is
presented in Figure 3. Catalase activity significantly reduced by 17%
(p<0.05, Figure 3A) in G6PD deficient participants compared with
their G6PD non-deficient counterparts. Similarly, a 16% reduction in
SOD activities was observed in G6PD deficient participants but this
drop was not statistically significant (Figure 3A). However, no
significant difference (p>0.05) was observed in the blood
concentrations of MDA and protein carbonyl in both G6PD deficient
and non-deficient participants (Figure 3B). Similar, HbA1c values were
observed not to be significantly different (p>0.05) in G6PD deficient
and non-deficient participant (Figure 3C).
Figure 3: Oxidative stress indices among G6PD deficient and G6PD
non-deficient patients. Values are expressed as mean ± SEM with
n=102 for G6PD non-deficient patients and n=46 for G6PD
deficient patients (T2D). *p<0.05 compared with G6PD non-
deficient patients for each parameter.
Relationship between G6PD deficiency and type 2 diabetes
In total, 46 of 148 patients were G6PD deficient with an overall
prevalence of 31.1%. Among these patients, 24 (16.4%) were T2D
while 22 (14.9%) were ND patients. Chi square analysis carried out to
assess the relationship between T2D and G6PD deficiency showed no
significant relationship between G6PD deficiency and T2D (χ2=0.217;
p=0.641) as shown in Table 2. Since G6PD is a sex-linked disorder, the
relationship between G6PD and T2D was assessed independently for
each sex. Chi square analysis as shown in Table 2 showed significant
relationship between G6PD deficiency and T2D in males (χ2=5.070;
p=0.024). Among the females, 27 were deficient of which 10 were
homozygous while 17 were heterozygous (intermediate). However, no
significant association (χ2=1.164; p=0.281) was observed between
G6PD deficiency and T2D in females (Table 2).
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  Diabetes status Computed χ
2
value
Standard χ2 value at
p=0.05 p-value
  T2D ND Total    
G6PD
status
Deficient 24 (16.2%) 22 (14.9%) 46 (31.1%)
0.217 3.841 0.641Non-deficient 49 (33.1%) 53 (35.8%) 102 (68.9%)
Total 73 (49.3%) 75 (50.7%) 148 (100%)
Sex G6PD Status Diabetes status Computed χ
2
value
Standard χ2 value at
p=0.05 p-value
  T2D ND Total    
Male
Deficient 12 (22.2% 7 (13.0%) 19 (35.2%)
5.07 3.841 0.024Non-deficient 11 (20.4%) 24 (44.4%) 35 (64.8%)
Total 23 (42.6%) 31 (57.4%) 54 (100%)
Female
Deficient 12(12.8%) 15 (16.0%) 27 (28.7%)
1.164 3.841 0.281Non-deficient 38 (40.4%) 29 (30.9%) 67 (71.3%)
Total 50 (53.2%) 44 (46.8%) 94 (100%)
Table 2: Relationship between G6PD deficiency and T2D (A) and in male and female (B).
Interaction between T2D and G6PD deficiency on
antioxidant and oxidative stress markers
A two-way analysis of variance computed to further investigate the
interaction between G6PD deficiency and T2D on antioxidant and
oxidative stress indices revealed no significant difference in the data set
at p<0.05 as shown Table 3.
Parameters
(n=148)







































HbA1c (%) 8.8 ± 1.65 7.3 ± 2.96 13.0 ±2.3
4.25 ±
4.56 0.347
Table 3: Interaction between T2D and G6PD deficiency on antioxidant
and oxidative stress markers.
Correlation between antioxidant, oxidative stress indices, age
and FBG
Analysis of the correlation between antioxidant enzymes, markers of
oxidative stress, age and FBG levels is summarised in Table 4. Results
of the analysis indicated that age significantly (p<0.05) correlated
positively with protein oxidation and negatively with catalase while
FBG significantly (p<0.05) correlated positively with MDA and protein
oxidation. No statistically significant correlation was observed between
age or FBG with other antioxidants and markers of oxidative stress.
(n=148)
Catalase































8 0.01 0.241 0.004
Table 4: Correlation between age, FBG, antioxidant and oxidative
stress indices. r=Pearson correlation.
Discussion
T2D is a disease characterized by high levels of glucose in blood
(hyperglycaemia) and it’s usually prevalent in people above 40 years of
age. Hyperglycaemia is known to induce the formation of free radical
[4], promoting oxidative stress and damage to cellular macromolecules
such as lipids, proteins and nucleic acids [12]. Lipid peroxidation by
free radicals produces highly reactive aldehydes such as MDA which
damages cell membranes [15]. This provides the basis for the
consideration of serum MDA level as a biomarker for free radical-
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mediated lipid damage and oxidative stress [36]. The significantly
(p<0.001) high levels of MDA in T2D participants observed in this
study confirms previous reports of elevated levels of thiobarbituric
acid-reactive substances (TBARS) in the serum as well as in red blood
cells of diabetes patients [37].
Endogenous proteins are targets for free radical attacks via the
oxidation of methionine, cysteine, and/or tyrosine residues; forming
carbonyls as the oxidation product. Therefore, there is a direct link
between the generation of free radicals (such as observed in T2D) and
increased serum levels of protein carbonyls [38]. In agreement with
previous studies, this study revealed significantly high levels (p<0.001)
of protein carbonyl content in T2D compared with ND participants
[38].
Measurement of blood levels of HbA1c has becomes a classical
method for assessing the extent of oxidative damage resulting from
hyperglycaemia and glycaemic control in T2D. It is clearly understood
that, due to prolonged hyperglycaemia, autoxidation of glucose occurs
and the resulting oxidized glucose (free radicals) condenses non-
enzymatically with protein in blood, particularly haemoglobin [39]. As
such, elevated levels of blood glucose in T2D could increase the level of
HbA1c. As expected, findings in this study showed significantly higher
level (p<0.05) of HbA1c in T2D patients compared to the control. The
significantly high levels of protein oxidation, lipid peroxidation as well
as HbA1c in T2D participants suggest T2D to promote oxidative stress.
More so, this study showed FBG to positively correlate with protein
oxidation as well as lipid peroxidation suggesting possible influence of
T2D on oxidative stress as previously reported [40].
Increase in oxidative stress (lipid peroxidation, protein oxidation
and HbA1c) due to glucose autoxidation may possibly affect or inhibit
the activities of enzymatic and non-enzymatic antioxidants as previous
reported [40-42]. In congruence with this assertion, our study showed
significantly (p<0.05) reduced activities of SOD and catalase activity in
T2D patients. This observation is consistent with previous reports of
reduced SOD [43,44] and catalase [45] activities as well as reduced
total antioxidants level [46] in T2D patients. This may be due to the
debilitating effects of high levels of free radicals damaging antioxidant
producing cells. Reduced erythrocyte antioxidant enzyme activities
have been reported in T2D condition [47]. Likewise, reduced catalase
activities in patients with diseases associated with oxidative stress, such
as atherosclerosis and schizophrenia, has been reported [48]. The
increase in protein and lipid oxidation damage as well as reduced
activities of antioxidant enzymes further attributes T2D to promote
oxidative stress [49,50].
With the depletion of enzymatic antioxidants, the body relies on
non-enzymatic antioxidant sources or other physiological molecules to
supplement the antioxidant defence system against oxidative stress.
One of such physiological molecule is NADPH. NADPH plays a
critical role in the regeneration of GSH, a non-enzymatic antioxidant
that decomposes free radicals to non-reactive species in the body [26].
NADPH is produced by G6PD in the pentose phosphate pathway
during the metabolism of Glucose-6-phosphate [51]. Due to its
immensely important role in free radical scavenging, it is logical to
think that G6PD deficiency may promote oxidative stress and be
associated with T2D. This study showed similar levels of oxidative
stress markers in G6PD deficient and non-deficient participants
suggesting that G6PD deficiency did not influence oxidative stress as
previously reported by Obasa et al. [52] which reported no association
between oxidative stress and G6PD deficiency in babies. More so,
when the relationship between G6PD deficiency and T2D was
assessed, this finding revealed no significant relationship between the
two parameters as previously reported [27-29]. However, further
comparison of the relationship between G6PD deficiency and T2D
independently in male and female showed a significant association in
male patients. This suggests that G6PD deficiency may be associated
with T2D in male patients. On the other hand, there was no
association between G6PD deficiency and T2D in female patients.
Similar finding has been reported previously showing association
between G6PD deficiency and diabetes among men but not in women
[53].
Available research evidence with respect to the relationship between
diabetes and G6PD deficiency indicates divergent opinions. For
instance, our results agree with the findings of Heymann et al. [29]
which showed G6PD deficiency as a potential risk factor for diabetes
but conflicts with the reports of Adinortey et al. [54]. Even though
extensive statistical analysis conducted in this study to investigate the
interaction between G6PD deficiency and T2D on oxidative stress
showed no significant relationship, there was possible association
between G6PD deficiency and T2D in male patients. It is therefore
important that research efforts are dedicated to resolving this divergent
view of the role of G6PD in the development of oxidative stress in T2D.
Conclusion
This study showed possible association between G6PD deficiency
and T2D in male patients. These findings also indicate an association
between oxidative stress and T2D as significantly increased levels of
lipid peroxidation, protein oxidation and HbA1c was observed in T2D
participants coupled with reduced activities of antioxidant enzymes in
the same cohort. However, oxidative stress was not associated with
G6PD deficiency neither did G6PD deficiency interact with T2D to
influence oxidative stress. Further investigations may be necessary to
better explain the contribution of G6PD deficiency to the development
of oxidative stress in T2D as there are conflicting reports on the
association between these parameters.
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